Поспішай повільно: Японія затвердила першу COVID-вакцину wz.lviv.ua - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from wz.lviv.ua Daily Mail and Mail on Sunday newspapers.
Takeda Pharmaceutical Company Limited
Takeda Submits New Drug Application to Manufacture and Market Darvadstrocel In Japan for Treatment of Complex Perianal Fistulas in Adult Patients with Crohn s Disease
Wednesday, February 10, 2021 12:15PM IST (6:45AM GMT)
Takeda Applies for Approval for the Company’s First Allogeneic Stem Cell Therapy in Japan
If Approved, Darvadstrocel Would Offer a Potential Cell-Mediated Closure Option for Adult Patients in Japan Who Do Not Respond to Conventional or Biologic Therapies for Complex Perianal Fistulas in Crohn’s Disease
1,2
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that it has submitted an application to the Japanese Ministry of Health, Labour and Welfare to manufacture and market darvadstrocel (development code: Cx601) for the treatment of complex perianal fistulas in adult patients with non-active/mildly active luminal Crohn’s disease (CD).
Search jobs 10-Feb-2021 Takeda Submits New Drug Application to Manufacture and Market Darvadstrocel In Japan for Treatment of Complex Perianal Fistulas in Adult Patients with Crohn’s Disease
Takeda Submits New Drug Application to Manufacture and Market Darvadstrocel
In Japan for Treatment of Complex Perianal Fistulas in Adult Patients with Crohn’s Disease
−
Who Do Not Respond to Conventional or Biologic Therapies for Complex Perianal Fistulas in Crohn’s Disease[i]
Osaka, JAPAN, February 10, 2021 –Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that it has submitted an application to the Japanese Ministry of Health, Labour and Welfare to manufacture and market darvadstrocel (development code: Cx601) for the treatment of complex perianal fistulas in adult patients with non-active/mildly active luminal Crohn’s disease (CD).
Le Japon va jeter des millions de doses de vaccin Pfizer en raison d une pénurie de seringues cnews.fr - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from cnews.fr Daily Mail and Mail on Sunday newspapers.
Operator
Good day, everyone, and welcome to today s Neurocrine Biosciences Reports Fourth Quarter and Year-End 2020 Results. [Operator Instructions] [Operator Instructions]
It is now my pleasure to turn the conference over to Vice President of Investor Relations, Todd Tushla.
Todd Tushla
Vice President of Investor Relations
Thank you, Clorey. Good afternoon, everyone, and thank you for joining us on our fourth quarter and full year 2020 earnings call. On the call today is Kevin Gorman, our Chief Executive Officer; Matt Abernethy, our Chief Financial Officer; Eiry Roberts, our Chief Medical Officer; Eric Benevich, our Chief Commercial Officer; and Kyle Gano, our Chief Business Development and Strategy Officer.